Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Trinity Biotech ( (TRIB) ) has provided an announcement.
Trinity Biotech has announced that it received early approval from the World Health Organization to commence offshore manufacturing of its rapid HIV tests, TrinScreen HIV and Uni-Gold HIV. This milestone is part of the company’s Comprehensive Transformation Plan aimed at reducing manufacturing costs and is expected to enhance future growth, improve profit margins, and increase shareholder value as they begin production at the new location in the first quarter of 2025.
More about Trinity Biotech
Trinity Biotech is a commercial-stage biotechnology company specializing in human diagnostics and diabetes management solutions, including wearable biosensors. The company develops and markets diagnostic systems for the point-of-care and clinical laboratory segments, focusing on infectious diseases and diabetes-related metrics. Trinity Biotech operates globally, selling directly in the United States and through international distributors in over 75 countries.
YTD Price Performance: -60.47%
Average Trading Volume: 172,111
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $9.63M
See more insights into TRIB stock on TipRanks’ Stock Analysis page.
Trending Articles
- ‘The Boom Isn’t Over Yet,’ Says Top Investor About Ripple (XRP)
- TD Bank (TSE:TD) Gets Upgrade From BMO Capital
- Apple and Nvidia Partner to Enable Faster LLM Token Generation
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
